Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Wilke, MH"'
Publikováno v:
Infektiologie Update 2018; 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG); 20181004-20181006; Wien; DOC18peg25 /20181008/
Einführung: Bei einer Reihe von Infektionen (z.B. komplizierte Haut-Weichteilinfektionen (ABSSI) und tiefen Wundinfektionen) ist eine lange intravenöse Therapiedauer erforderlich. MRSA spielt hier als Erreger immer noch eine wichtige Rolle. Mit Dal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e314ee1af6ee3160e1ce154ab46c9d4d
Publikováno v:
European Journal of Medical Research, Vol 16, Iss 12, p 543 (2011)
Abstract Introduction The management of bloodstream infections especially sepsis is a difficult task. An optimal antibiotic therapy (ABX) is paramount for success. Procalcitonin (PCT) is a well investigated biomarker that allows close monitoring of t
Externí odkaz:
https://doaj.org/article/b19da95d26d34820b8974658536b2e95
Publikováno v:
European Journal of Medical Research, Vol 16, Iss 7, p 315 (2011)
Abstract Introduction Hospital-acquired pneumonia (HAP) often occurring as ventilator-associated pneumonia (VAP) is the most frequent hospital infection in intensive care units (ICU). Early adequate antimicrobial therapy is an essential determinant o
Externí odkaz:
https://doaj.org/article/8126f3e6ddb84b5d815d06877f965032
Autor:
Wilke MH
Publikováno v:
European Journal of Medical Research, Vol 16, Iss 4, p 180 (2011)
Abstract Invasive fungal infections are on the rise. Echinocandins are a relatively new class of antifungal drugs that act by inhibition of a key enzyme necessary for integrity of the fungal cell wall. Currently there are three available agents: casp
Externí odkaz:
https://doaj.org/article/14a42ab4a571451a9b14db78a8f890cd
Publikováno v:
European Journal of Medical Research, Vol 15, Iss 12, p 564 (2010)
Abstract The cost of treatments especially in conditions where multiresistant bacteria are involved are a major issue in times where in most developed countries in the world payment systems based on diagnoses-related-groups (DRG) are in place. There
Externí odkaz:
https://doaj.org/article/7afd4649625e4b4781b2f462222216dc
Autor:
Wilke MH
Publikováno v:
European Journal of Medical Research, Vol 15, Iss 12, p 571 (2010)
Abstract Severe infections with multiresistant bacteria (MRB) are a medical challenge and a financial burden for hospitals. The adequate antibiotic therapy is a key issue in multiresistant bacteria management. Several major cost drivers have been ide
Externí odkaz:
https://doaj.org/article/a246c8993d454fa088cf1c3c479e8e7b
Publikováno v:
Bad Honnef-Symposium 2016; 20160321-20160322; Bonn; DOC16bhs14 /20160316/
Die frühe, korrekte Therapie mit wirksamen Antibiotika stellt den wichtigsten Erfolgsfaktor bei bakteriellen Infektionen dar. Patienten genesen schneller, sterben seltener und erleiden weniger Komplikationen. Diese Erkenntnis gilt in der Infektiolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5036469ed3664bdb65cbfa832527e8f2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Wilke MH; Medical School Hamburg (MSH), Am Kaiserkai 1, 20456, Hamburg, Germany. Michael.wilke@medicalschool-hamburg.de., Preisendörfer B; Inspiring-Health GmbH, Waldmeisterstrasse 72, 80935, Munich, Germany., Seiffert A; Gesundheitsforen Leipzig GmbH, Hainstraße 16, 04109, Leipzig, Germany., Kleppisch M; Health Technology Assessment and Outcomes Research (HTA&OR), Health and Value Germany, Pfizer Pharma GmbH, Linkstraße 10, 10785, Berlin, Germany.; Hospital Business Unit Germany, Pfizer Pharma GmbH, Linkstraße 10, 10785, Berlin, Germany., Schweizer C; Health Technology Assessment and Outcomes Research (HTA&OR), Health and Value Germany, Pfizer Pharma GmbH, Linkstraße 10, 10785, Berlin, Germany.; Hospital Business Unit Germany, Pfizer Pharma GmbH, Linkstraße 10, 10785, Berlin, Germany., Rauchensteiner S; Health Technology Assessment and Outcomes Research (HTA&OR), Health and Value Germany, Pfizer Pharma GmbH, Linkstraße 10, 10785, Berlin, Germany.; Hospital Business Unit Germany, Pfizer Pharma GmbH, Linkstraße 10, 10785, Berlin, Germany.
Publikováno v:
Infection [Infection] 2022 Dec; Vol. 50 (6), pp. 1535-1542. Date of Electronic Publication: 2022 May 31.